The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells

Blood. 2002 Dec 15;100(13):4454-61. doi: 10.1182/blood-2002-02-0415. Epub 2002 Jun 28.

Abstract

Thrombin signaling in endothelial cells provides an important link between coagulation and inflammation. We report here that thrombin induces endogenous Egr-1 mRNA and Egr-1 promoter activity in primary human endothelial cells by approximately 6-fold and 3-fold, respectively. In transient transfection assays, deletion of the 3' cluster of serum response elements (SREs), but not the 5' cluster of SREs, resulted in a loss of thrombin response. When coupled to a heterologous core promoter, a region spanning the 3' SRE cluster contained information for thrombin response, whereas a region spanning the 5' SRE cluster had no such effect. A point mutation of the most proximal SRE (SRE-1), but not of the proximal Ets motif or upstream SREs, abrogated the response to thrombin. In electrophoretic mobility shift assays, nuclear extracts from thrombin-treated cells displayed increased binding of total and phosphorylated serum response factor (SRF) to SRE-1. Thrombin-mediated induction of Egr-1 was blocked by inhibitors of MEK1/2, but not by inhibitors of protein kinase C, phosphatidylinositol 3-kinase, or p38 mitogen-activated protein kinase (MAPK). Taken together, these data suggest that thrombin induces Egr-1 expression in endothelial cells by a MAPK-dependent mechanism that involves an interaction between SRF and SRE-1.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Motifs
  • Cells, Cultured / cytology
  • Cells, Cultured / drug effects
  • Culture Media, Serum-Free / pharmacology
  • DNA-Binding Proteins / biosynthesis
  • DNA-Binding Proteins / genetics*
  • Early Growth Response Protein 1
  • Electrophoretic Mobility Shift Assay
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Enzyme Inhibitors / pharmacology
  • Genes, Reporter
  • Genes, Synthetic
  • Humans
  • Immediate-Early Proteins*
  • Luciferases / biosynthesis
  • Luciferases / genetics
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • MAP Kinase Signaling System / drug effects
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Point Mutation
  • Protein Binding / drug effects
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Transport / drug effects
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • RNA, Messenger / biosynthesis
  • Sequence Deletion
  • Serum Response Element / drug effects*
  • Serum Response Factor / pharmacology*
  • Thrombin / pharmacology*
  • Transcription Factors / biosynthesis
  • Transcription Factors / genetics*
  • Transcriptional Activation / drug effects
  • Transfection

Substances

  • Culture Media, Serum-Free
  • DNA-Binding Proteins
  • EGR1 protein, human
  • Early Growth Response Protein 1
  • Enzyme Inhibitors
  • Immediate-Early Proteins
  • RNA, Messenger
  • Serum Response Factor
  • Transcription Factors
  • Luciferases
  • MAP2K2 protein, human
  • Protein-Tyrosine Kinases
  • Protein Serine-Threonine Kinases
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • MAP2K1 protein, human
  • Mitogen-Activated Protein Kinase Kinases
  • Thrombin